September 2017- Volume 13, Issue 9

In this Issue

Feature

Guest Commentary: Affinity and beyond--Assessing the alternatives to therapeutic antibodies

Guest Commentary: Affinity and beyond--Assessing the alternatives to therapeutic antibodies

New technological developments that would benefit from a new breed of affinity binders include antibody-drug conjugates that link cytotoxic drugs to targeting binders, bi-specific affinity molecules that concurrently target multiple biological pathways and new affinity reagents for the evolution of in-vivo imaging. These technologies have the potential to fundamentally reshape the industry, not only offering essential healthcare cost savings, but also to provide new medicines with improved safety and efficacy for patients.

Patent Docs: Federal Circuit Loosens Requirements for Finding Inequitable Conduct

Patent Docs: Federal Circuit Loosens Requirements for Finding Inequitable Conduct

Earlier this month, the Federal Circuit affirmed a decision by a district court that the patent at issue before it had been obtained through inequitable conduct. However, contrary to prevailing standards the district court used litigation misconduct rather than malfeasance during patent prosecution to justify its decision, raising fears that lawyers involved in obtaining patents for their clients may be found liable for conduct of (other) lawyers representing their clients in litigation.

Show Preview: The genome goes to Orlando

Show Preview: The genome goes to Orlando

ASHG 2017 meeting to showcase the latest on the human genome

Q&A

Q&A: In-vivo models of infectious disease

Q&A: In-vivo models of infectious disease

We speak to Adriano Flora, associate director of the Scientific Program Management Group at Taconic Biosciences

Commentary

Guest Commentary: De-risking drug development

Guest Commentary: De-risking drug development

Can the pharma world better select new molecules that will have a greater than a 1:10,000 chance of progressing through development and making a successful, safe, marketed product?

Out of order: Significant, but relevant?

Out of order: Significant, but relevant?

There seems to be an assumption that if something is statistically significant, it is medically relevant. The corollary would imply that something determined not statistically significant is therefore not medically relevant. But is this true? And medically relevant for whom?

Diagnostics

Invitae to acquire CombiMatrix

Invitae to acquire CombiMatrix

Combined company hopes to tap power of genetics to inform health decisions when starting a family

Biological Dynamics advances exosome isolation technique

Biological Dynamics advances exosome isolation technique

ExoVerita lab-on-a-chip system can simplify and streamline the isolation and recovery of exosomes

Two is better than one

Two is better than one

Biodesix’s GeneStrat and VeriStrat tests for non-small cell lung cancer pass with flying colors

Research & Development

Microsystems with a big impact

Microsystems with a big impact

Research uses new polymer chip model to grow biomimetic microtissue

Race in the race against AD

Race in the race against AD

UC Davis awarded more than $14 million for Alzheimer’s disease study in Latinos

Simplified synthesis

Simplified synthesis

Rice University team details new approach for synthesizing aminating agents

Lilly and Purdue form strategic research collaboration

Lilly and Purdue form strategic research collaboration

Lilly will provide the university up to $52 million to fund life-sciences research over five years

Streamlining bispecifics

Streamlining bispecifics

Merck KGaA uses Genedata functionalities to scale up bispecific antibody discovery programs

Clinical Trials

Going after gonorrhea

Going after gonorrhea

Entasis and GARDP partner to develop treatment for increasing threat of resistant gonorrhea

Dueling with Duchenne

Dueling with Duchenne

PTC Therapeutics publishes ACT DMD Phase 3 trial data

An impressive Phase 2 for Reata

An impressive Phase 2 for Reata

Company advances bardoxolone in Alport syndrome based on significant kidney function improvement

Adding Japan to GALACTIC-HF

Adding Japan to GALACTIC-HF

Cytokinetics announces positive results for omecamtiv mecarbil in Japanese heart failure patients

Business & Government Policy

Pairing up against autoimmunity

Pairing up against autoimmunity

Eli Lilly and Nektar join forces to seek new treatment for autoimmune conditions

On the move

On the move

Avantor and BioTek expand; labfolder joins Merck Accelerator

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Co-developing tisotumab vedotin for solid tumors

Co-developing tisotumab vedotin for solid tumors

Seattle Genetics exercises option; costs to be split equally with Genmab going forward

Contract Services

INC Research propels Catalyst into psychiatric arena

INC Research propels Catalyst into psychiatric arena

New offering joins existing Oncology and Vaccine networks in the Catalyst suite

A more vigilant Quanticate

A more vigilant Quanticate

With the thalidomide tragedy still in mind decades later, U.K. CRO heightens pharmacovigilance

WuXi merges two units

WuXi merges two units

STA Pharmaceutical combines with Pharmaceutical Development Services division

Discovery

ReadCoor, WAVE Life Sciences collaborate for research

ReadCoor, WAVE Life Sciences collaborate for research

Partners aim to unlock next-generation stereopure nucleic acid targets with FISSEQ technologies

‘Building on excellent experiences’

‘Building on excellent experiences’

Max Planck Innovation, Daiichi Sankyo and the Lead Discovery Center to pursue cancer lead discovery

Rare disease research

Rare disease research

NIH team identifies cause of muscle disorder CFZS

Blocking key enzyme may reverse memory loss

Blocking key enzyme may reverse memory loss

MIT study suggests a new approach to developing treatments for Alzheimer’s disease

Another AI alliance

Another AI alliance

Exscientia shares artificial intelligence capacity with top pharmaceutical partner

Preclinical

Good news with NOX

Good news with NOX

France’s Genkyotex launches GKT831 to target CAFs, delay tumor growth

Subcutaneous success

Subcutaneous success

Catalyst sees encouraging activity levels in vivo for Factor IX, VIIa products

Immunovaccine personalizes cancer immunotherapies

Immunovaccine personalizes cancer immunotherapies

DepoVax system successfully combines 14 neoepitope cancer peptides into one formulation

Progress on ABX464

Progress on ABX464

Compound dampens intestinal inflammation by triggering IL-22 production in activated macrophages

Inventiva publishes IVA337 data

Inventiva publishes IVA337 data

Results support therapeutic potential of the pan-PPAR agonist for the treatment of NASH

Special Reports

Editor's Focus

The treasures in our trove

The treasures in our trove

A look at the bonuses to be found on the DDNews websites with our Editconnect codes
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

December 2021/January 2022 Issue

Latest Issue  

• Volume 17 • Issue 12 • December 2021/January 2022

December 2021/January 2022

December 2021/January 2022 Issue